Edition:
United States

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

7.59USD
15 Dec 2017
Change (% chg)

$0.28 (+3.90%)
Prev Close
$7.31
Open
$7.30
Day's High
$7.81
Day's Low
$7.23
Volume
89,503
Avg. Vol
53,829
52-wk High
$10.24
52-wk Low
$2.43

Select another date:

Thu, Dec 14 2017

BRIEF-Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock

* DICERNA ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK

BRIEF-Dicerna Pharmaceuticals Files Preliminary Prospectus Supplement Related To A Potential Common Stock Offering

* DICERNA PHARMACEUTICALS INC FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL COMMON STOCK OFFERING - SEC FILING Source text : (http://bit.ly/2o22t2b) Further company coverage:

BRIEF-Dicerna announces proposed public offering of common stock

* DICERNA PHARMACEUTICALS INC - TO USE PROCEEDS FROM OFFERING FOR PRECLINICAL STUDIES & CLINICAL TRIALS Source text for Eikon: Further company coverage:

BRIEF-Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC

* DICERNA ANNOUNCES FIRST HUMAN DOSED IN PHASE 1 CLINICAL TRIAL OF DCR-PHXC FOR TREATMENT OF ALL FORMS OF PRIMARY HYPEROXALURIA

BRIEF-Dicerna Pharmaceuticals Q3 loss per share ‍$0.92

* Q3 2017 loss per share ‍$0.92 Source text for Eikon: Further company coverage:

BRIEF-Boehringer, Dicerna collaborate to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis

* Boehringer Ingelheim and Dicerna announce collaboration to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis (NASH)

Alnylam loses bid to toss Dicerna counterclaims in trade secrets case

Drugmaker Alnylam Pharmaceuticals has lost its bid to dismiss counterclaims that rival Dicerna Pharmaceuticals asserted in response to a trade secrets lawsuit brought by Alnylam two years ago.

BRIEF-Dicerna files clinical trial application for DCR-PHXC for phase 1 study in hyperoxaluria

* Dicerna files clinical trial application for DCR-PHXC, the company’s most advanced GalXC™ product candidate, for phase 1 study in primary hyperoxaluria (ph)

BRIEF-Dicerna Q2 net loss per share $1.15

* Dicerna reports second quarter 2017 financial and operating results and provides corporate update

Sparring over trade secrets, biotech brings new antitrust suit against rival

Dicerna Pharmaceuticals has filed an antitrust lawsuit against Alnylam Pharmaceuticals, escalating a legal fight between two rival biotech companies developing a type of treatment for a series of rare metabolism disorders.

Select another date: